Baseball Greats, Amgen Launch Multiple Myeloma Awareness Campaign
Backed by former Major League Baseball All-Stars Dave Winfield and Steve Garvey, Amgen has launched a program aimed at raising awareness of multiple myeloma,…
News
Darzalex Combination Approved in Europe for Some Newly Diagnosed Multiple Myeloma Patients
The European Commission has approved the anti-CD38 antibody Darzalex (daratumumab), in combination with standard therapy, for newly diagnosed multiple myeloma patients who cannot receive a stem…
Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial
Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory…
Some with Smoldering Multiple Myeloma May Benefit from Immediate Treatment, Study Suggests
Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor of multiple myeloma — often exhibits similar genetic alterations as the full-blown disease, suggesting that patients could…
Combining Simple Blood Tests Might Accelerate Diagnosis of Myeloma
The combination of two blood tests routinely ordered by general practitioners could speed the diagnosis of myeloma, according to a new study. The research,…
Revlimid-based Therapies are Best Maintenance Option for Newly-diagnosed Multiple Myeloma Patients, Analysis Finds
Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “…
Amgen Seeks Expanded Approval of Kyprolis to Once-weekly Regimen for Relapsed Myeloma
Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for…
FDA Grants Priority Review to Empliciti Combo Therapy for Relapsed or Refractory Myeloma
The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and…
BL-8040 Speeds Collection of Stem Cells for Transplant in Myeloma Patients, Phase 3 Data Suggest
Adding BioLineRx‘s BL-8040 to standard treatment greatly improves the mobilization of blood stem cells to be collected for stem cell transplants in patients…
Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma
SRF231, an experimental anti-CD47 immunotherapy candidate developed by Surface Oncology, was granted orphan drug status by the U.S. Food and Drug Administration for…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL